IOncology

A patient-level analysis of the phase III CheckMate 77T trial (NCT04025879) and the phase III CheckMate 816 trial (NCT02998528) revealed that perioperative treatment with nivolumab for resectable non-small cell lung cancer (NSCLC) patients reduces the risk of disease recurrence or death by approximately 40%, compared to neoadjuvant nivolumab plus chemotherapy alone. This article presents Dr. Yong Song from General Hospital of Eastern Theater Command’s insights on the analysis results (Abstract PL02.07).

EGFR P-loop-aC helix compression (PACC) mutation is a recently identified subtype of EGFR mutations in non-small cell lung cancer (NSCLC), and its potential for precision therapy had not been clinically validated until now. At the 2024 World Conference on Lung Cancer (WCLC 2024), during the Presidential Symposium Presentation, the global phase Ib FURTHER trial's proof-of-concept results were revealed. Furmonertinib as monotherapy in first-line treatment of NSCLC patients with EGFR PACC mutations demonstrated outstanding efficacy and safety. Oncology Frontier  interviews the study’s principal investigator, Dr. Xiuning Le from the MD Anderson Cancer Center, to delve into how EGFR PACC mutations moved from concept to clinic and how Furmonertinib is pioneering targeted therapy for this subtype of lung cancer.

The 2024 World Conference on Lung Cancer (WCLC), taking place from September 7-10 in San Diego, USA, will showcase key findings from Chinese researchers, including a phase III randomized controlled trial comparing plinabulin plus docetaxel versus docetaxel alone for the treatment of advanced non-small cell lung cancer (NSCLC) after progression on platinum-based chemotherapy. The results of this study will be presented during the "OA08 – New Generation of Cytotoxic Agents" session and published in The Lancet Respiratory Medicine on the same day.

During the second Presidential Symposium at the 2024 World Conference on Lung Cancer (WCLC), Professor Jing-Ji Yang from Guangdong Provincial People’s Hospital presented the report “Osimertinib with or without Savolitinib as First-Line Treatment for De Novo MET Aberrant, EGFRm Advanced Non-Small Cell Lung Cancer (NSCLC) (CTONG 2008): Results from the Phase II FLOWERS Clinical Trial.”

The 2024 European Society for Medical Oncology (ESMO) Congress took place from September 13 to 17 in Barcelona, Spain, where significant progress in lung cancer research was unveiled. Dr. Ben J. Solomon, from the Peter MacCallum Cancer Centre in Melbourne, Australia, shared the results of the biomarker analysis from the ALINA study. In an exclusive interview with Oncology Frontier, Professor Solomon discussed the efficacy, safety, and biomarker analysis of alectinib in ALK-positive non-small cell lung cancer (NSCLC) patients. He also highlighted the latest advancements in targeted therapies for ALK-positive and KRAS G12C-mutant NSCLC.

Ilourac (WX-0593) is a next-generation, potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), showing both systemic and central nervous system (CNS) efficacy in patients with ALK-positive non-small cell lung cancer (NSCLC). At the 2024 ESMO Congress, updated data from the INSPIRE study were presented in a poster session, showing continued progression-free survival (PFS) improvement with ilourac compared to crizotinib in advanced ALK-positive and ALK TKI-naive NSCLC patients. Safety findings were consistent with previous results, with no new safety concerns observed. In this article, Oncology Outlook invited Dr. Xiao Chen from The First Bethune Hospital of Jilin University to provide commentary on the updated data from this study (Abstract #1278P).

The 2024 European Society for Medical Oncology (ESMO) Annual Meeting has successfully concluded. Several studies presented during the neuroendocrine tumor (NET) oral sessions have offered new treatment strategies and molecular profiling for advanced unresectable NETs. Notably, the Phase III CABINET study on cabozantinib achieved its primary endpoint of progression-free survival (PFS), and the multi-center single-arm CVM-005 study showed impressive PFS results with the anti-vasculogenic mimicry drug CVM-1118, especially when combined with SSA (somatostatin analogs), with the median PFS for extra-pulmonary NETs reaching nearly two years. Furthermore, multi-omics profiling has provided a foundation for prognostic assessment, classification-based treatment, and biomarker exploration in NETs. Oncology Frontier invited Dr. Jie Chen from Fudan University Shanghai Cancer Center to introduce and comment on these studies.

The 2024 World Conference on Lung Cancer (WCLC) was held in San Diego from September 7-10, featuring major studies from Chinese scholars. Oncology Frontier had the opportunity to interview Dr. Baohui Han from Shanghai Chest Hospital, inviting her to interpret the results of the DUBLIN-3 and DURABLE clinical trials.

Thrilled to share our interview with Professor Guohong Han about the LEAP-012 study, which could revolutionize liver cancer treatment! Combining TACE with lenvatinib and pembrolizumab is showing incredible results for intermediate-stage liver cancer: 46.8% tumor response rate Progression-free survival boosted from 10 to 14.6 months

In a recent Media Medic interview, our colleague El Bachir MOURABIT had the privilege to speak with Dr. Fred Saad about breakthrough advancements in metastatic hormone-sensitive prostate cancer (mHSPC) treatment. Dr. Saad emphasized the importance of combining androgen deprivation therapy (ADT) with ARPIs like apalutamide, enzalutamide, or abiraterone for improved survival. He also shared promising results from the Phase 3 ARINOTE study, showcasing darolutamide with ADT as a safe and effective option, especially for patients who may not tolerate chemotherapy.